CamBMT1: A proof of principle phase 1b/randomised phase 2 study of afatinib penetration into brain metastases (mets) for patients undergoing neurosurgical resection, both with …

Background: Failure of drugs to cross the blood brain barrier (BBB) can be a major reason for treatment failure for patients with brain tumours. For most patients who don't respond to treatment, it is not known whether this is due to inadequate drug concentrations in the tumour, or due to drug resistance. Preliminary data suggest that low-dose radiotherapy may disrupt the BBB, and could facilitate increased drug delivery into brain tumours. Afatinib is a potent, irreversible inhibitor of EGFR/HER2/HER4 and takes approximately 8 days to achieve steady-state concentrations in cancer patients. CamBMT1 has been designed to investigate the delivery of afatinib into brain mets and whether this might be enhanced by low dose-radiotherapy.Trial design: Study population: patients with operable...© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights …